News

Video

Organizations Can Help Patients with CML Face the ‘Long Treatment Journey’

Author(s):

A chronic myeloid leukemia diagnosis can negatively affect patients and their loved ones’ mental health, but there are resources that can help.

A diagnosis of chromic myeloid leukemia (CML) can lead to a “long treatment journey,” but there are organizations and resources that can help with some of the common issues patients and their loved ones face, said Claire Saxton, executive vice president of Insights and Impact at Cancer Support Community.

In an interview with CURE® at the 2024 American Society of Clinical Oncology Annual Meeting, Saxton discussed where patients with CML and caregivers can look for help. These organizations can offer services such as financial counseling, support groups and mental health professionals.

“This is a long treatment journey, and there is a huge impact on your life and your family’s life, and also on your mental health,” Saxton said in the interview.

READ MORE: Mending the Mind After Cancer

Transcript:

This is a long treatment journey, and there is a huge impact on your life on your family's life and also on your mental health.

Reach out for resources. It can be hard to find them initially, but there are a number of patient advocacy groups like Cancer Support Community, [Leukemia & Lymphoma Society], CML Buster [Foundation] who are here and ready to help with financial counsellors, support groups, access to mental health professionals, because those are the kinds of things that are going to help give you the support that you need to get through this long term.

Editor's Note: This program was made possible with support from Novartis Pharmaceuticals.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Image of two people.
Image of doctor.
Image of woman.
Related Content